Enhancing Drug Quality and Safety Takes Priority in SFDA Chief's Discussions at Amsterdam Summit
Saudi Food and Drug Authority CEO Dr. Hisham S. Aljadhey engages with international counterparts to strengthen regulatory cooperation and enhance pharmaceutical safety standards.
RIYADH: Saudi Food and Drug Authority CEO Dr. Hisham S.
Aljadhey participated in a series of high-level meetings during the International Coalition of Medicines Regulatory Authorities Summit 2025, held in Amsterdam from October 21-23.
The discussions focused on bolstering cooperation and communication between regulatory bodies to achieve common objectives aimed at improving the safety, quality, and efficacy of medicines and vaccines.
Meetings were held with Dr. Leandro Safatle, director-president of the Brazilian Health Regulatory Agency, as well as two bilateral meetings with Dr. Ali El-Ghamrawy, chairman of the Egyptian Drug Authority, and Lawrence Tallon, chief executive of the British Medicines and Healthcare Products Regulatory Authority.
Topics of mutual interest included leading practices and policies on artificial intelligence to foster innovation and growth in the pharmaceutical sector.
The International Coalition of Medicines Regulatory Authorities (ICMRA) serves as an international platform for enhancing collaboration among regulatory bodies.
This cooperation aims to address drug safety challenges through innovative mechanisms and develop related regulatory frameworks and systems.
Aligning with the objectives of the health sector transformation program under Saudi Arabia's Vision 2030, these discussions signify a significant step towards strengthening global regulatory standards in the pharmaceutical industry.
Aljadhey participated in a series of high-level meetings during the International Coalition of Medicines Regulatory Authorities Summit 2025, held in Amsterdam from October 21-23.
The discussions focused on bolstering cooperation and communication between regulatory bodies to achieve common objectives aimed at improving the safety, quality, and efficacy of medicines and vaccines.
Meetings were held with Dr. Leandro Safatle, director-president of the Brazilian Health Regulatory Agency, as well as two bilateral meetings with Dr. Ali El-Ghamrawy, chairman of the Egyptian Drug Authority, and Lawrence Tallon, chief executive of the British Medicines and Healthcare Products Regulatory Authority.
Topics of mutual interest included leading practices and policies on artificial intelligence to foster innovation and growth in the pharmaceutical sector.
The International Coalition of Medicines Regulatory Authorities (ICMRA) serves as an international platform for enhancing collaboration among regulatory bodies.
This cooperation aims to address drug safety challenges through innovative mechanisms and develop related regulatory frameworks and systems.
Aligning with the objectives of the health sector transformation program under Saudi Arabia's Vision 2030, these discussions signify a significant step towards strengthening global regulatory standards in the pharmaceutical industry.
